Drugmaker Merck said Wednesday that the devaluation of Venezuela's currency will reduce its net income by about $200 million this year.

Merck will take a charge of 5 cents per share in the first quarter as a result of the devaluation of the bolivar. The devaluation will reduce the company's net income by about 2 cents per share over the rest of the year.